Consumption of Buglossoides arvensis seed oil is safe and increases tissue long-chain n-3 fatty acid content more than flax seed oil: results of a phase I randomised clinical trial
Lefort N, LeBlanc R, Giroux MA, Surette ME
Published in Journal of Nutritional Science
Methodology
Phase I randomized clinical trial comparing Buglossoides arvensis (Ahiflower) seed oil with flaxseed oil and a corn oil control over 28 days, measuring blood and tissue fatty acid composition and safety markers.
Key Findings
Ahiflower oil raised eicosapentaenoic acid (EPA) and total long-chain n-3 content in blood and cells significantly more than flaxseed oil, consistent with stearidonic acid bypassing the rate-limiting delta-6-desaturase step. No adverse effects on safety biomarkers were seen. Docosahexaenoic acid (DHA) did not increase.
Conclusions
Ahiflower oil is a safe plant-based route to raising EPA status more efficiently than flaxseed oil, but it does not raise DHA.
Limitations
Small phase I sample, 28-day duration, biomarker endpoints only with no clinical outcomes, and industry supply of the test oil.
Supplements Studied
Ahiflower oil raised EPA and total long-chain n-3 content more than flaxseed oil over 28 days, with no adverse safety signals, but did not raise DHA.
Ahiflower oil raised eicosapentaenoic acid (EPA) and total long-chain n-3 content in blood and cells significantly more than flaxseed oil, consistent with stearidonic acid bypassing the rate-limiting delta-6-desaturase step. No adverse effects on safety biomarkers were seen. Docosahexaenoic acid (DHA) did not increase.
Study Details
Access Study
Disclosures
Funding
Study oil supplied by the Ahiflower producer; academic conduct (Université de Moncton).
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.